MinervaX, a Copenhagen, Denmark-based biotechnology company, raised EUR54M in upsized financing.
The round was led by EQT Life Sciences and OrbiMed, with participation from existing investors Novo Holdings, Pureos Ventures, Sanofi Ventures, Trill Impact Ventures, Adjuvant Capital, Wellington Partners, Industrifonden, Sunstone LifeScience Ventures, and LF Invest.
The company intends to use the funds to support its efforts to commence a Phase III clinical trial of its Maternal Vaccine against Group B Streptococcus.
Established in 2010 and led by CEO Per Fischer, MinervaX is a biotechnology company advancing a prophylactic vaccine against Group B Streptococcus (GBS), based on research from Lund University. It is developing a GBS vaccine for maternal immunization, and now also for vaccination of older adults, with Phase II data suggesting superior efficacy compared with other GBS vaccine candidates in development. The latter are based on traditional capsular polysaccharide (CPS) conjugate technology. By contrast, its vaccine is a protein-only vaccine based on fusions of highly immunogenic and protective protein domains from selected surface proteins of GBS (the Alpha-like protein family).
FinSMEs
11/10/2023